Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

The reverse transcriptase inhibitor efavirenz is currently used at a fixed dose of 600 mg/d. However, dosage individualization based on plasma concentration monitoring might be indicated. This study aimed to assess the efavirenz pharmacokinetic profile and interpatient versus intrapatient variability in patients who are positive for human immunodeficiency virus, to explore the relationship between drug exposure, efficacy, and central nervous system toxicity and to build up a Bayesian approach for dosage adaptation.

[1]  Patrick F. Smith,et al.  Clinical Pharmacokinetics of Non-Nucleoside Reverse Transcriptase Inhibitors , 2001, Clinical pharmacokinetics.

[2]  R. Maserati,et al.  Pharmacokinetic variability and strategy for therapeutic drug monitoring of saquinavir (SQV) in HIV-1 infected individuals. , 1999, British journal of clinical pharmacology.

[3]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[4]  Jacques Fellay,et al.  Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.

[5]  A. Telenti,et al.  Simultaneous determination of the HIV protease inhibitors indinavir, amprenavir, saquinavir, ritonavir, nelfinavir and the non-nucleoside reverse transcriptase inhibitor efavirenz by high-performance liquid chromatography after solid-phase extraction. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[6]  A. Telenti,et al.  Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study , 2001, AIDS.

[7]  R Rode,et al.  Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.

[8]  P. Diggle,et al.  Semiparametric models for longitudinal data with application to CD4 cell numbers in HIV seroconverters. , 1994, Biometrics.

[9]  Jogarao V. S. Gobburu,et al.  Application of Resampling Techniques to Estimate Exact Significance Levels for Covariate Selection During Nonlinear Mixed Effects Model Building: Some Inferences , 2004, Pharmaceutical Research.

[10]  C. Fletcher.  Pharmacologic Considerations for Therapeutic Success with Antiretroviral Agents , 1999, The Annals of pharmacotherapy.

[11]  D. Richman,et al.  Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients , 2000, AIDS.

[12]  A. Telenti,et al.  Efavirenz Plasma Levels Can Predict Treatment Failure and Central Nervous System Side Effects in Hiv-1-infected Patients , 2022 .

[13]  M. Dudley,et al.  A Population Pharmacokinetic Analysis of Nelfinavir Mesylate in Human Immunodeficiency Virus-Infected Patients Enrolled in a Phase III Clinical Trial , 2000, Antimicrobial Agents and Chemotherapy.

[14]  Higher efavirenz plasma levels correlate with development of insomnia. , 2001, Journal of acquired immune deficiency syndromes.

[15]  P. Reiss,et al.  The influence of efavirenz on the pharmacokinetics of a twice‐daily combination of indinavir and low‐dose ritonavir in healthy Volunteers , 2002, Clinical pharmacology and therapeutics.

[16]  Douglas M. Bates,et al.  Nonlinear Regression Analysis and Its Applications , 1988 .

[17]  J. Pachón,et al.  Pharmacokinetic Interactions Between Efavirenz and Rifampicin in HIV-Infected Patients with Tuberculosis , 2002, Clinical pharmacokinetics.

[18]  L B Sheiner,et al.  Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.

[19]  U. Brinkmann,et al.  Frequency of C3435T polymorphism of MDR1 gene in African people , 2001, The Lancet.